Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Consortium to tackle PTSD
October 2019
SHARING OPTIONS:

GENEVA—Addex Therapeutics has announced plans to lead a consortium that will focus on developing small-molecule negative allosteric modulators (NAMs) that target the metabotropic glutamate receptor 7 (mGlu7) as a possible treatment for the reduction of fear memory in post-traumatic stress disorder (PTSD). In addition to Addex, participants include Naason Science, Endotherm, Nucro Technics and Radboud University. Eurostars has awarded the consortium, DiSARM FEAR, a €4.85-million grant to fund the research. The goal is to have novel mGlu7 NAMs ready to begin IND-enabling studies within three years.
 
“This Eurostars grant is a significant validation of the pioneering discovery work we have been doing in the field of mGlu7 and in particular the field of PTSD, a significant and growing unmet medical need,” said Robert Lütjens, head of Discovery Biology at Addex.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.